GET DAILY SIGNALSWhy Is Cryoport (CYRX) Stock Up +20.44% Today?
Key Takeaways
- CYRX shares surged more than 20% in Thursday's session, climbing to roughly $19.33 from a prior close of $16.05.
- The primary catalyst was a strong third-quarter earnings report, with revenue of $50.2 million beating consensus estimates.
- Management raised full-year 2026 revenue guidance to $197–$199 million, signaling confidence in the cell and gene therapy pipeline.
- Several analysts responded by lifting price targets, including Needham's upgrade to $28 from $19.
- Investors are now watching upcoming FDA decision dates and the company's path toward sustained profitability.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages for CYRX.
- Discover the strongest-performing AI-driven trading strategies on Tickeron's Trending AI Robots page.
Opening Summary
Cryoport, Inc. (CYRX), a global provider of temperature-controlled supply chain solutions for the life sciences industry with a focus on cell and gene therapies, saw its stock rally sharply in Thursday's trading. Shares climbed roughly 20.44% to approximately $19.33, up from a prior closing price of $16.05. The advance followed the company's third-quarter 2026 earnings report, released after the market closed the previous day, which delivered better-than-expected revenue growth and an upward revision to full-year guidance.
Earnings Results and Guidance
The dominant driver behind the move was Cryoport's third-quarter results. The company reported revenue of $50.2 million, up 14% year-over-year from continuing operations and ahead of the consensus estimate of approximately $48.7 million. Life Sciences Services revenue grew 18% and accounted for 57% of total revenue, while commercial cell and gene therapy revenue rose 20% year-over-year.
Although the company posted a net loss of $0.25 per share, slightly wider than the $0.18 loss analysts had modeled, investors focused on the operational momentum. Cryoport delivered its second consecutive quarter of positive adjusted EBITDA, at $1.1 million, a $1.8 million improvement year-over-year. Management also raised its full-year 2026 revenue guidance to a range of $197 million to $199 million, reflecting confidence in its commercial therapy base and a record clinical trial pipeline of 788 trials, including 99 in Phase 3.
Analyst Upgrades and Price Target Raises
The earnings-driven rally was reinforced by a wave of bullish analyst action. Needham maintained its Buy rating and raised its price target to $28 from $19, citing revenue upside and improving operational efficiency. Craig-Hallum lifted its target to $22 from $20, and KeyBanc raised its target to $20 while reiterating an Overweight rating. The synchronized upward revisions amplified positive sentiment and contributed to the magnitude of the single-day gain.
Market Context and Trading Activity
Trading activity reflected elevated investor interest, with volume running well above the stock's typical daily turnover as buyers responded to the guidance raise and analyst endorsements. The move stood out against a broader small- and mid-cap life sciences backdrop, as the shares broke decisively through short-term technical resistance levels established during the prior week's consolidation. The gap higher on strong volume suggests conviction among investors positioned for continued execution on the company's profitability pathway.
What Comes Next for CYRX
Looking ahead, traders are watching several catalysts for CYRX. The company flagged upcoming FDA Prescription Drug User Fee Act (PDUFA) decision dates for client therapies in the fourth quarter, which could influence future revenue visibility. Management also noted that some biologic license and marketing authorization filings previously expected in 2026 have slipped into 2027, a factor that introduces some uncertainty around near-term growth acceleration. Investors will also monitor utilization at newly opened global supply chain facilities in Paris and Santa Ana, which could initially pressure gross margins before contributing operating leverage. The balance between robust cell and gene therapy demand and the company's path toward sustained profitability remains central to the investment thesis.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot differing by strategy, timeframe, performance metrics, and the symbols it trades. Only the most resilient and top-performing strategies are featured in this section, giving traders a focused view of automated approaches. Explore the Trending AI Robots page to see which strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CYRX in upward trend: price rose above 50-day moving average on November 06, 2026
CYRX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 41 of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where CYRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CYRX as a result. In 78 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYRX advanced for three days, in 213 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 177 of 203 cases where CYRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for CYRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 18 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Moving Average Convergence Divergence Histogram (MACD) for CYRX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 48 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
CYRX broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CYRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.177) is normal, around the industry mean (2.490). CYRX has a moderately low P/E Ratio (-21.222) as compared to the industry average of (7.427). CYRX's Projected Growth (PEG Ratio) (62.128) is very high in comparison to the industry average of (5.110). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (4.437) is also within normal values, averaging (2.034).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Accounting Profit?
Will My Pension Payments Affect My Social Security Payments?
AI-Driven Trend Analysis: Emphasizing Mid-Cap Stocks in Long Positions
What Are Covered Calls and Their Risks?
The Tata Group Empire Forecast 2030: Why This Indian Mega-Conglomerate Could Become One of the Biggest Wealth-Creation Machines of the Decade
General Information
a provider of cryogenic logistics solutions to the life sciences industry
Industry OtherTransportation
Advertisement